Filing Details
- Accession Number:
- 0001209191-20-007022
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-05 17:55:00
- Reporting Period:
- 2020-02-03
- Accepted Time:
- 2020-02-05 17:55:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1701541 | Black Diamond Therapeutics Inc. | BDTX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1613867 | Ali Behbahani | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-02-03 | 2,176,957 | $0.00 | 2,176,957 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2020-02-03 | 471,800 | $0.00 | 2,648,757 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2020-02-03 | 800,000 | $19.00 | 3,448,757 | No | 4 | P | Indirect | See Note 2 |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Note 2 |
No | 4 | C | Indirect | See Note 2 |
No | 4 | P | Indirect | See Note 2 |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2020-02-03 | 6,565,290 | $0.00 | 2,176,957 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2020-02-03 | 1,422,862 | $0.00 | 471,800 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date.
- The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEAPartners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial ownerof the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, asamended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest.
- Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date.